CanSino Biologics Says Its Vaccine Causes No Serious Blood Clots

Chinese drugmaker CanSino Biologics said its single-dose COVID-19 vaccine, Ad5-nCoV, which uses adenovirus-vector technology like that used in the AstraZeneca (AZ) and Johnson & Johnson (J&J) vaccines, has not seen any reports of serious blood clots.

Co-developed with a research arm of the Chinese military, CanSino’s vaccine is currently authorized for use in China, Pakistan, Hungary, Chile and Mexico, but is still being evaluated in multiple clinical trials in China, Russia and elsewhere.

Adenovirus-based vaccines from AZ and J&J vaccines, which have been linked to very rare but potentially life-threatening blood clots, are currently undergoing safety reviews by U.S. and EU regulators.